ARTICLE SUMMARY:
Corvista Health hopes to provide an extra layer of certitude for patients suspected of coronary artery disease and pulmonary hypertension. Its FDA-cleared noninvasive test for the point of care expands upon the ECG with additional sensors and AI to rule in or rule out coronary artery disease. A second noninvasive test for patients suspected to have pulmonary hypertension received FDA clearance and Breakthrough Device Designation.
Corvista Health (the US subsidiary of Analytics 4 Life) is offering a noninvasive test designed to be used widely to make sure that patients with cardiovascular disease are followed appropriately. The company is testing symptomatic patients for coronary artery disease and pulmonary hypertension, where providing an extra layer of triage has value, says Chief Scientific Officer and Executive VP Charles Bridges, MD, ScD. “We’re targeting patients that have cardiovascular symptoms, including, but not limited to, shortness of breath, chest pain, syncope, swelling of the ankles, edema, and congestion.” It is not a screening test, he says.
